Daily Stock Analysis, IMMU, Immunomedics Inc, priceseries

Immunomedics Inc. Daily Stock Analysis
Stock Information
Open
14.99
Close
15.49
High
15.55
Low
14.84
Previous Close
14.93
Daily Price Gain
0.56
YTD High
19.51
YTD High Date
Apr 1, 2019
YTD Low
11.55
YTD Low Date
Jan 18, 2019
YTD Price Change
0.51
YTD Gain
3.40%
52 Week High
26.99
52 Week High Date
Sep 4, 2018
52 Week Low
11.55
52 Week Low Date
Jan 18, 2019
52 Week Price Change
-10.43
52 Week Gain
-40.24%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 5. 2017
6.36
Jun 1. 2017
7.31
18 Trading Days
14.91%
Link
LONG
Aug 18. 2017
8.42
Sep 12. 2017
11.76
16 Trading Days
39.67%
Link
LONG
Dec 19. 2017
13.46
Jan 16. 2018
15.53
17 Trading Days
15.40%
Link
LONG
Apr 10. 2018
15.28
Apr 23. 2018
16.26
9 Trading Days
6.42%
Link
LONG
May 15. 2018
18.78
Jun 11. 2018
23.90
18 Trading Days
27.26%
Link
LONG
Aug 27. 2018
23.57
Sep 6. 2018
25.07
7 Trading Days
6.38%
Link
LONG
Nov 29. 2018
18.95
Dec 4. 2018
20.04
3 Trading Days
5.75%
Link
LONG
Feb 22. 2019
14.89
Mar 22. 2019
17.67
20 Trading Days
18.70%
Link
Company Information
Stock Symbol
IMMU
Exchange
NasdaqGM
Company URL
http://www.immunomedics.com
Company Phone
9736058200
CEO
David M. Goldenberg
Headquarters
New Jersey
Business Address
300 AMERICAN RD, MORRIS PLAINS, NJ 07950
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000722830
About

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. The company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It markets and sells its products in the U.S. and throughout Europe. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.

Description

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and epratuzumab, a humanized antibody that targets CD22, an antigen found on the surface of B lymphocytes. Its early-stage products include IMMU-114, a novel humanized antibody for the treatment of patients with B-cell and other cancers; Milatuzumab, a humanized monoclonal antibody targeting tumors that expresses the CD74 antigen, which is present on various hematological tumors and solid cancers; Veltuzumab, a humanized monoclonal antibody targeting CD20 receptors on B lymphocytes for the treatment of non-Hodgkin lymphoma and autoimmune diseases; and Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled anti-CD22 investigational product. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.